Hypertriglyceridemia Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Hypertriglyceridemia Treatment Market is Segmented By Drug Class (Fibrates, Omega-3 Fatty Acids, Statins, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Market Overview

Global Hypertriglyceridemia Treatment Market is expected to reach at a high CAGR during the forecast period 2023-2030.

The global hypertriglyceridemia treatment market experiencing significant growth in recent years with various factors influencing its dynamics such as increasing prevalence, changing lifestyles, rising clinical trials, and others. Government investments in better treatment will continue to drive and boost the global market. The global hypertriglyceridemia treatment industry is placing increasing emphasis on development of the innovative therapeutics to reduce its impact. 

Hypertriglyceridemia is characterized by too many triglycerides (fats) in the blood. It may leads to the risk of atherosclerosis and related heart diseases. A normal triglyceride level in adults should be below 150 milligrams per deciliter (mg/dL). A triglyceride level below 100 mg/dL is considered ideal. Hypertriglyceridemia causes when the triglyceride level is 150 mg/dL or higher. 

Moreover, the treatment of hypertriglyceridemia includes fibrates such as fenofibrate, omega-3 fatty acids such as icosapent ethyl (IPE), statins, and others.  The fibrates segment holds the largest market share over the forecast period and is considered as first-line treatment for hypertriglyceridemia. Similarly, North America dominates the market, capturing the largest market share owing to the region’s favorable reimbursement policies, advanced healthcare infrastructure, and presence of major players. 

Owing to the factors such as the increasing prevalence of hypertriglyceridemia, growing awareness about the unhealthy diet, rising clinical trials, increasing demand for novel therapeutics, increasing research activities and regulatory approvals, and advancements in treatment options are the major factors expected to drive the global market over the forecast period. However, the availability of alternative treatment options is expected to hamper the market growth over the forecast period.

Report Scope

For more details on this report Request for Sample

Market Dynamics

Rising Regulatory Approvals and Clinical Trials are Expected to Drive the Growth of the Market

The rising regulatory approvals and clinical trials for hypertriglyceridemia treatment are expected to drive market growth over the forecast period. Regulatory approvals such as FDA approvals, NMPA approvals, and others for new medications and therapies mean a broader range of treatment options for hypertriglyceridemia patients, which increases the trust in patients about medication usage. This can lead to improved patient outcomes with better results.

For instance, on June 01, 2023, Amarin Corporation plc announced that its commercial partner in China, EddingPharm (EDDING), has received regulatory approval for VASCEPA (icosapent ethyl) from China’s National Medical Products Administration (NMPA). NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).

Furthermore, the clinical trials not only demonstrate the safety and efficacy of new treatments but also generate valuable data that can be used for regulatory submissions about new and existing medications. This process can expedite the approval of innovative therapies. The positive results from clinical trials can boost investor confidence and patient trust in the usage of medicines for hypertriglyceridemia treatment. This increased confidence can attract funding for further research and development and conduct more clinical trials, allowing companies to invest in more innovative therapeutics and driving the market growth.

For instance, on May 23, 2023, 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety, and tolerability of pegozafermin in patients with severe hypertriglyceridemia (SHTG). 

Increasing Demand for Therapeutic Innovations is Also Expected to Drive the Growth of the Market

The increasing demand for therapeutic innovations is also expected to drive the growth of the market over the forecast period. There are some significant unmet medical needs for more effective and targeted treatments for hypertriglyceridemia, especially in cases of severe conditions. This creates a demand for innovative therapies which can provide better outcomes. These discoveries can lead to the development of novel therapeutic targets and innovative treatment approaches.

Moreover, innovative approaches may involve combining existing medications, such as fibrates and statins, in novel ways to optimize their effects while minimizing side effects. Many drugs are also developing as adjuncts for the existing drugs for better treatment. Combination therapies can offer innovative solutions for severe hypertriglyceridemia conditions. There are still existing many treatment advancements that results in better treatment outcomes. These advancements increase the way for the introduction of novel drugs and devices with different mechanisms of action.

For instance, on March 21, 2023, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces it has launched Icosapent Ethyl Capsules in 0.5g dose. The product, launched in the US, is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. 

Availability of Alternative Treatment Options is Expected to Hamper the Market's Growth

The availability of alternative treatment options is expected to hamper the market growth over the forecast period. Lifestyle changes, like adopting a healthier diet, avoiding alcohol, avoiding refined carbohydrates and sugars, increasing physical activity, and replacing saturated fats and trans fats with healthier fats can effectively lower triglyceride levels. These non-pharmacological approaches are often the first line of treatment and can be highly effective when followed diligently.

Moreover, the availability of natural methods helps patients for better results with fewer side effects. These natural methods of lifestyle modifications are considered a first-line treatment for hypertriglyceridemia, which is expected to hamper the growth of the market.

Segmentation Analysis

The global hypertriglyceridemia treatment market is segmented based on drug class, distribution channel and region.

The Fibrates Segment Accounted for Approximately 47% of the Hypertriglyceridemia Treatment Market Share

The fibrates segment holds the largest market share over the forecast period. They are mainly considered as a first-line treatment in the treatment of hypertriglyceridemia. They usually work by activating the peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor involved in lipid metabolism. This unique mechanism specifically targets triglyceride metabolism, making fibrates particularly effective in reducing elevated triglyceride levels. 

Additionally, fibrates can markedly lower triglyceride levels (40 to 60 percent) and modestly raise HDL-C levels (15 to 25 percent). In patients with cardiovascular disease and moderately elevated triglyceride levels and low HDL-C levels, fibrates have been shown to decrease the risk of cardiovascular events. Fibrates are often used in combination with other lipid-lowering medications, such as statins, to address multiple aspects of lipid disorders. This combination therapy can provide more comprehensive control over lipid profiles, especially when patients have both high triglycerides and high LDL cholesterol levels.

Geographical Shares

North America Accounted for Approximately 39% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and well-established healthcare infrastructure. North America is well-known for its well-established healthcare infrastructure including hospitals, specialty clinics, ambulatory surgical centers, research centers, and others, which offers better treatment for hypertriglyceridemia patients. This presence of advanced healthcare infrastructure provides favorable insurance coverage to patients for treatment at affordable costs. 

North America especially the United States and Canada is a home for many pharmaceutical and medical device companies, this major presence actively performs in clinical trials, and research activities to develop enhanced therapeutic innovations which results in better patient outcomes. By actively performing clinical trials, they get appropriate funding and investments to develop innovative treatments for better treatment of hypertriglyceridemia.

For instance, on December 1, 2022, PTC Therapeutics, Inc. announced that the Brazilian Health Regulatory Agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria), has approved Waylivra (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This is the first approval globally for Waylivra for the FPL indication. Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS), which is characterized by severe hypertriglyceridemia (>880mg/dL).

Key Players

The major global players in the hypertriglyceridemia treatment market include Hikma Pharmaceuticals PLC, Woodward Pharma Services LLC, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Ionis Pharmaceuticals Inc., Mylan N.V., Accord Healthcare, Sun Pharmaceutical Industries Limited, and Amryt Pharma plc, among others. 

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global hypertriglyceridemia treatment market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus on the COVID-19 pandemic to develop medications for COVID-19.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide. Many hospitals are focused on COVID-19 cases, this reduced the hypertriglyceridemia treatments impact the market and further leads to the risks associated with the hypertriglyceridemia.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of hypertriglyceridemia-related drugs and other therapeutics. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for proper hypertriglyceridemia treatment due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global hypertriglyceridemia treatment market. The impact of the import and export of raw materials are temporarily disrupted. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region. 

Key Developments

• On March 09, 2023, a novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis. sHTG is a well-established risk factor for recurrent episodes of acute pancreatitis. These high-risk patients were the focus of a phase 2 study that was led by the Icahn School of Medicine at Mount Sinai and sponsored and funded by Regeneron.
• On January 31, 2023, Ionis Pharmaceuticals announced it received fast-track designation from the FDA for its investigational therapy, olezarsen, in patients with familial chylomicronemia syndrome (FCS). Olezarsen is also being investigated in Phase III clinical trial (NCT05079919) for severe hypertriglyceridemia (sHTG) in the US and several European countries, including France, Germany, Italy, and the UK.

DataM Intelligence Opinion:

According to the DataM Intelligence, the hypertriglyceridemia treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence, changing lifestyles, unhealthy diets, and novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. 

Moreover, combining drug therapies is evolving for better treatment. Many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global hypertriglyceridemia treatment market in the upcoming years.

Why Purchase the Report?

• To visualize the global hypertriglyceridemia treatment market segmentation based on drug class, distribution channel and region as well as understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of hypertriglyceridemia treatment market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global hypertriglyceridemia treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies